85%Confidence
0Views
FDASource
2026-03-18Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential supply chain disruptions for this oncology drug, which could affect patient access and increase scrutiny on Cipla's manufacturing quality. This may create opportunities for competitors in the tyrosine kinase inhibitor market while damaging Cipla's reputation with US regulators.
Actionable: Monitor Cipla's manufacturing compliance and consider alternative suppliers for nilotinib to mitigate supply risks.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now